Literature DB >> 9677472

Sequential methothrextate and 5-fruororacil therapy for diffuse bone metastasis from gastric cancer.

T Etoh1, H Baba, A Taketomi, H Nakashima, S Kohnoe, Y Seo, T Saito, H Tomoda.   

Abstract

We herein present a case of diffuse bone metastasis from early gastric cancer with disseminated intravascular coagulation (DIC) in a 40-year old man, who had undergone a curative gastrectomy and had no evidence of recurrence for five years after surgery. The patient was treated with an intravenous administration of sequential methothrexate (MTX) and 5-fluorouracil (5-FU), and demonstrated a favorable clinical course without any severe pain. Despite the fact that the presence of diffuse bone metastasis from gastric cancer plus hematologic disorders tends to indicate a significantly poor prognosis, the patient survived for a relatively long period (11 months) following chemotherapy. We thus conclude that MTX/5-FU sequential therapy seems to be a clinically useful regimen to improve both the symptoms and survival for cases of diffuse bone metastasis from gastric cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9677472

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  High circulating tumor cell concentrations in a specific subtype of gastric cancer with diffuse bone metastasis at diagnosis.

Authors:  Kazuhiro Shimazu; Koji Fukuda; Taichi Yoshida; Masahiro Inoue; Hiroyuki Shibata
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 2.  Current Progress in EBV-Associated B-Cell Lymphomas.

Authors:  Yonggang Pei; Alexandria E Lewis; Erle S Robertson
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

3.  Circulating tumor cell count as a biomarker of a specific gastric cancer subgroup characterized by bone metastasis and/or disseminated intravascular coagulation - an early indicator of chemotherapeutic response.

Authors:  Masahiro Inoue; Kazunori Otsuka; Hiroyuki Shibata
Journal:  Oncol Lett       Date:  2015-12-24       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.